Local cancer care holds its own against academic giants. A new Community Oncology Alliance analysis found that patients with metastatic breast cancer and non-small cell lung cancer treated in community practices outlived national benchmarks. Experts credit faster access, continuity of care, and proximity to home as key drivers — suggesting that for systemic therapy-driven cancers, staying local may be a strong option.
Think you need a big academic cancer center for the best outcomes? Not necessarily. A new analysis from the Community Oncology Alliance (COA) found that patients with de novo metastatic breast cancer and non-small cell lung cancer (NSCLC) treated in community oncology practices had notably longer median overall survival compared to patients in the national SEER registry. Community practices — which serve roughly 85% of US cancer patients — are increasingly proving their worth for advanced cancers managed primarily with systemic therapies.
Experts point to three key advantages: speed (same-day appointments for sick patients), continuity (patients see familiar faces who know their story), and location (staying close to home preserves family support and daily routines). As metastatic cancer increasingly resembles a chronic condition requiring long-term management, these factors carry real clinical weight.
By the Numbers:
Why it matters: The study has methodological caveats — the two databases aren't perfectly comparable — but it reinforces that community oncology delivers high-quality, guideline-concordant care. As academic centers expand regional networks and satellite clinics, the line between community and academic oncology is blurring, which could ultimately benefit patients everywhere.
